Standard of Care Treatment and Immunotherapy

When your brain is under attack from your own immune system, time is of the essence. In seronegative autoimmune encephalitis (AE), specialists often pursue a strategy of early immunotherapy when suspicion is high ^[1]. Because waiting weeks for antibody results can lead to permanent brain injury, the current standard of care is to start immunotherapy (treatment that calms the immune system) as soon as clinically appropriate once criteria are met and infections have been reasonably excluded ^[2][3].

Supportive care is just as vital as immunotherapy and should include anti-seizure treatments, sleep and agitation management, nutrition, and clot prevention.

The First Line of Defense

First-line treatments are designed to stop the immediate immune attack and reduce brain swelling. Most patients receive one or a combination of the following:

• High-Dose Corticosteroids: Usually given as “pulses” of intravenous (IV) methylprednisolone for 3 to 5 days ^[1]. These act like a “fire extinguisher” for brain inflammation. After the IV doses, you may be transitioned to a slow oral taper of prednisone to prevent the inflammation from returning ^[1]. Before starting steroids, it is important to know they carry risks of serious infection, high blood sugar, severe insomnia, mood or psychiatric effects, and bone complications, requiring glucose and blood pressure monitoring.
• IVIG (Intravenous Immunoglobulin): This treatment uses healthy antibodies from donors to neutralize the harmful ones in your system ^[4]. It is typically given daily for 5 days ^[4]. IVIG requires monitoring of kidney function and hydration, as it carries risks of severe headache, kidney injury, thrombosis (blood clots), and aseptic meningitis.
• Plasmapheresis (TPE/Plasma Exchange): This is a “blood-filtering” process. Your blood is cycled through a machine that removes the plasma (which contains the attacking antibodies and inflammatory proteins) and replaces it with a substitute ^[5]. This can be used as a primary therapy or rescue for patients who are very ill or who do not respond to steroids and IVIG ^[6]. It requires a central venous catheter (bringing infection risks) and can cause hypotension, bleeding, and electrolyte problems.

Escalating to Second-Line Therapy

If your symptoms do not improve significantly, your doctors may consider escalation ^[7][8]. Improvement can take longer than a week, and this timing is a specialist decision tailored to the patient. Delaying this step is associated with poorer long-term recovery ^[3].

• Rituximab: This is the most common second-line choice for seronegative patients ^[7]. It is a “targeted” therapy that removes B-cells (the cells that eventually produce antibodies). Evidence suggests it can be effective even when no specific antibody is found ^[9]. Because it suppresses the immune system, it carries significant risk of serious infections and requires screening for latent infections like Hepatitis B and Tuberculosis, as well as blood count monitoring.
• Cyclophosphamide: This is a more powerful, “broad-spectrum” immune-suppressing drug. It is typically reserved for the most severe cases where other treatments have failed, partly because it has a more significant side-effect profile ^[7][10]. It requires rigorous screening for severe infections and carries risks of bone marrow suppression and impacts on fertility or pregnancy.

Rescue Therapies for Refractory Cases

In rare, “refractory” cases—where the disease does not respond to first- or second-line treatments—doctors may use “third-line” or salvage therapies. These are often used for patients in the ICU with continuous seizures or coma:

• Tocilizumab: This drug blocks a specific inflammatory signal called IL-6. It has shown promise in helping patients who did not respond to Rituximab ^[11][12].
• Bortezomib: This is a “plasma-cell-targeting” drug. It goes after the very late-stage immune cells that produce antibodies, which other drugs might miss ^[13][14].

These specialist-directed, generally off-label options carry profound risks of immunosuppression and specific drug toxicities, and require close monitoring.

Why Early Treatment Matters

The inflammatory nature of AE means that the longer the inflammation lasts, the higher the risk of lasting cognitive or memory problems ^[15]. Studies show that patients who start immunotherapy within 30 days of their first symptoms generally have much better functional outcomes than those who wait ^[16][3].

In seronegative AE, the probable antibody-negative subtype can sometimes be more difficult to treat than cases with known antibodies ^[17]. This makes it even more important for your care team to be aggressive, adjusting the treatment plan appropriately if improvement isn’t seen ^[18].